$NEO

Aunan Greg D sold $321K of NEO

Aunan Greg D (Chief Accounting Officer) sold 20,000 shares of NEOGENOMICS INC (NEO) at $16.07 ($0.32M total) on 2026-08-04.

Original reporting
SEC EDGAR · Aunan Greg D
Published Aug 6, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 7:45 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NEO
Neutral
low confidence
Mentioned
$NEO
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NEONeutralLow
01

Why it matters

A single officer open-market sale can modestly affect sentiment, but it is not a fundamental datapoint like earnings, guidance, or a deal.

02

Market read

Traders may note the insider sale for sentiment, but there is no additional company-specific catalyst in the text.

03

What to watch

The filing does not include motives, and the post-sale holdings (5,153 shares) suggest the sale may be part of routine personal liquidity rather than a large conviction shift.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-06 for a sale dated 2026-08-04

Background

The article is an SEC Form 4 insider transaction disclosure for NEOGENOMICS.

Company-level read

Ticker impact

$NEONeutralLow confidence
Context

NEOGENOMICS insider Aunan Greg D sold 20,000 shares at $16.07 on 2026-08-04, per a newly filed Form 4.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless paired with other disclosures.

Evidence & confidence

Form 4 provides transaction details but no accompanying company-specific catalyst, guidance change, or regulatory/legal event.

Market effects

No clear sector read-through from a single insider sale.

None.

None.

Counterpoint

Insider sales are often planned for diversification or tax needs; the absence of a stated 10b5-1 plan does not automatically imply negative information.

Key entities

  • NEOGENOMICS INC

    Subject of the Form 4 insider transaction disclosure.

  • Aunan Greg D

    Chief Accounting Officer who sold shares.

Related articles

$NEOHighAI 9/10

NeoGenomics Q2 Earnings Call Highlights

NeoGenomics (NASDAQ: NEO) reported Q2 adjusted gross margin of 48.1% and adjusted EBITDA of $14.4 million. It raised 2026 revenue guidance to $802 million to $806 million and adjusted EBITDA to $56 million to $58 million. Management discussed RaDaR ST and PanTracer LBx reimbursement progress, NovaSeq X transitions, and a $316 million convertible note raise. Cash was $145.5 million.

$SPRCHighAI 8/10

Top Biotech Gainers: SPRC On Watch, AVTR, NEO Boost Full-Year Outlook, SMTI Scooped Up

Biotech gainers included SciSparc (SPRC) after its subsidiary NeuroThera Labs completed internal validation of a quantum sampling platform. Avantor (AVTR) rose after Q2 results and raised 2026 adjusted EPS to $0.80-$0.83. NeoGenomics (NEO) lifted 2026 revenue guidance to $802-$806M. Other movers: Alvotech (ALVO) on FDA facility inspection, Sanara MedTech (SMTI) to be acquired by MiMedx (MDXG), and LB Pharmaceuticals (LBRX) after a ~$150M private placement.

$NEOMedAI 9/10

Why NeoGenomics (NEO) Stock Is Up Today

NeoGenomics (NEO) shares rose 15.8% after the company reported Q2 2026 adjusted EPS of $0.05 on revenue of $201.7 million, beating Wall Street forecasts of $0.03 and $197.3 million. NeoGenomics also raised full-year guidance to about $804 million revenue and $0.19 adjusted EPS.

$NEOMedAI 8/10

NeoGenomics Inc (NEO) Q2 2026 Earnings Call Highlights: Strong Revenue Growth

NeoGenomics (NEO) reported Q2 2026 revenue of $201.7 million, up 11% year over year, with clinical revenue up 14% and NGS revenue up 26%. Adjusted gross margin rose to 48.1% and adjusted EBITDA increased to $14.4 million. Nonclinical/pharma revenue fell 26%. 2026 guidance was raised to $802-$806 million revenue and $56-$58 million adjusted EBITDA.

$NEOMed

NEOGENOMICS INC (NEO): Results of Operations and Financial Condition

NEOGENOMICS INC (NEO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a99-106302026earningsrelea.htm EX-99.1 Document Exhibit 99.1 NeoGenomics Reports Second Quarter 2026 Results Total revenue increased 11% YoY to $202 million Clinical services revenue grew 14%, with NGS revenue growth of 26% Company raises full-year 2026 revenue and adju